New antibody weapon targets stubborn blood cancers
NCT ID NCT04606433
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study is testing an experimental drug called GNC-038, a quad-specific antibody designed to attack cancer cells from multiple angles. It is for people with relapsed or refractory non-Hodgkin lymphoma or acute lymphoblastic leukemia who have not responded to other treatments. The main goals are to check the drug's safety, find the right dose, and see if it shrinks tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GNC-038 (a quad-specific antibody injection)
What this could lead to
If successful, this could lead to a new treatment option for people with blood cancers that have not responded to standard therapies.
What could go wrong
This is a very early Phase 1 trial with only 47 participants, so it is primarily testing safety and dosing. The antibody may not work well or could cause serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, China
-
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China
-
Hematology Hospital, Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, 300000, China
-
Nanfang Hospital of Southern Medical University
Guangzhou, Guangdong, China
-
Peking University Third Hospital
Beijing, Beijing Municipality, China
-
Shanghai Tongji Hospital
Shanghai, Shanghai Municipality, China
-
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China
-
The Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
-
The Second Hospital of Anhui Medical University
Hefei, Anhui, China
-
Xiangya Hospital Central South University
Changsha, Hunan, China